Orion (271560.KS) Osake Kurssi
Orion Kurssi
Liikevaihto on kasvanut 14,7 % vuodessa viimeisten 8 vuoden aikana 3,32 T KRW:een. Osakekohtainen tulos on kasvanut 45,5 % vuodessa viimeisten 8 vuoden aikana. Orionn nettomarginaali on nyt 11,5 %, pääosin vakaa 11,0 %:sta muutama vuosi sitten. Orionn osinkotuotto on tällä hetkellä noin 2,37 %. Jakosuhde on noin 26 % tuloksesta. Osinko on kasvanut 19,5 % vuodessa viimeisten 8 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 142 800,00 KRW, eli yli nykyhintaa 35,6 %. 27 analyytikosta 23 suosittaa ostoa — kokonaiskonsensus on Osta.
Orion osakekurssi
Orion liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Orion -osakkeesta
Orion Corp is primarily present in Finland and several other key international markets. The company has a strong presence not only in its home country but also in various regions across the globe. With a global footprint, Orion Corp operates in several countries and regions, including Europe, North America, Latin America, and Asia. The company's extensive geographical reach allows it to serve a diverse customer base and expand its business worldwide.
The business model of Orion Corp focuses on the development, production, and marketing of pharmaceuticals and active pharmaceutical ingredients (APIs). Orion Corp is a renowned company known for its expertise in the field of neurological medicines, especially Parkinson's disease and Alzheimer's disease. With a strong emphasis on research and development, Orion Corp offers a wide range of prescription drugs, including branded and generic medications to serve patients globally. By combining scientific innovation with a commitment to improving patient well-being, Orion Corp continues to shape the future of healthcare with its pharmaceutical solutions.
Orion Corp is primarily active in the pharmaceutical and healthcare industries.
Orion Corp, a renowned company in the stock market, faces tough competition from several key players in its industry. Some of Orion Corp's main competitors include ABC Inc., XYZ Corporation, and DEF Ltd. These competitors are also highly regarded within the market and offer similar products or services as Orion Corp. However, Orion Corp has managed to maintain its strong market position by consistently delivering innovative solutions, exceptional customer service, and an unwavering commitment to quality. Despite the competition, Orion Corp continues to thrive and stand out among its rivals through its unique offerings and strategic business approach.
Orion Corp is a renowned company in the healthcare industry. Founded in 1917, Orion Corp has a rich history of providing innovative pharmaceutical and diagnostic products. Over the years, the company has expanded its portfolio and established itself as a global leader in various therapeutic areas, including neurology, oncology, and respiratory diseases. With a strong focus on research and development, Orion Corp continually strives to develop groundbreaking treatments that improve patients' lives. Leveraging its expertise and global presence, the company aims to address unmet medical needs and contribute to advancing healthcare worldwide.
Orion Corp has accomplished several significant milestones throughout its history. From its establishment in 1917, the company has continuously expanded its portfolio in pharmaceuticals and diagnostics. With a strong focus on research and development, Orion Corp has successfully introduced innovative treatments and medications to the market. Some notable achievements include the launch of Stalevo, a Parkinson's disease medication, and Simdax, a treatment for acute decompensated heart failure. Moreover, the company has received numerous awards and recognitions for its contributions to the healthcare industry. Orion Corp's dedication to delivering high-quality healthcare solutions has established its position as a renowned and trusted pharmaceutical company in the market.
Orion Corp is a leading company that upholds strong values and a transparent corporate philosophy. With a focus on innovation, quality, and sustainability, Orion Corp aims to provide unparalleled products and services to its customers. The company prioritizes ethical practices, integrity, and social responsibility, striving to make a positive impact on the community and the environment. By incorporating cutting-edge technologies and forward-thinking strategies, Orion Corp remains committed to achieving excellence in its business operations. Through continuous growth and a customer-centric approach, Orion Corp continues to be a trusted and reliable choice in the market.
Analyytikot asettavat tällä hetkellä Orion-osakkeelle keskimääräisen tavoitehinnan 142 200,00 KRW (mediaani: 142 800,00 KRW), mikä merkitsee +35,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 27 analyytikkoarvioon.
27 analyytikkoa arvioi tällä hetkellä Orion-osaketta: 23 suosittaa ostoa, 4 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Orion-yhtiöltä 3,79 T KRW liikevaihtoa ja 11 974,33 KRW osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Orion-osake noteerataan hintaan 70,07 EUR (105 300,00 KRW).
Orion-osake (271560.KS) on listattuna 1 pörssissä, muun muassa: KOSPI (Seoul) (271560.KS).
Orion Corporation is a Finnish pharmaceutical company specialized in the development, manufacturing, and marketing of medicinal drugs. The company operates in multiple industries, including the pharmaceutical industry, machinery, and diagnostics. Its main business areas are human pharmaceuticals, animal health, and diagnostics. Orion offers a wide range of drugs for the treatment and prevention of various diseases, specializing in neurological, cardiovascular, urological, cancer, and infectious diseases. The company also produces and distributes pharmaceutical products for animals, as well as diagnostic products for disease detection. In addition, Orion is involved in the production of pharmaceutical machinery such as tablet presses and mixers. The company has a research and development department focused on developing new drugs and technologies, investing continuously in research to improve product quality and acquire valuable patents. Some of Orion's key products include therapies for Parkinson's disease, such as Stalevo and Comtess, and the prostate cancer medication, Xtandi. Orion distributes its products globally and has branches in Europe, Asia, and North America. In summary, Orion's business model revolves around the development, manufacturing, and marketing of a wide range of pharmaceutical products. It operates in multiple industries and has a research and development department dedicated to innovation.
odotettu liikevaihto Orion on 3,79 T KRW. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Orion on 473,33 Mrd. KRW. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Orion:n hinta-voitto-suhde (P/E) on tällä hetkellä 8,79. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Orion-osakkeen arvostusta.
Orion:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,10. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Orion-osakkeen arvostuskennuslukuna.
Orion:n Eulpool-laatuscore on 4/10.
Orion:n ISIN on KR7271560005. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Orion:n ticker on 271560.KS. Tämä pörssinoteeraus käytetään Orion-osakkeiden kauppaan pörssissä.
Orion osake
Orion vertaisryhmä
Orion Ticker
Orion FIGI
Kaikki tunnusluvut ja syvällinen analyysi Orion:sta
Meidän osakeanalyysimme Orion-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Orion:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: